GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascelia Pharma AB (OSTO:ACE) » Definitions » Future Policy Benefits

Ascelia Pharma AB (OSTO:ACE) Future Policy Benefits


View and export this data going back to 2019. Start your Free Trial

What is Ascelia Pharma AB Future Policy Benefits?

Future Policy Benefits only applies to insurance companies.


Ascelia Pharma AB Business Description

Traded in Other Exchanges
Address
Hyllie Boulevard 34, Malmo, SWE, 215 32
Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.